Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024 ...

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Resea ...

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal first quarter ending June 30, 2024, on August 14, 2024, and will host a conference call to discuss these results and recent corporate developments [1] Financial Results Announcement - Aethlon Medical will issue its financial results at 4:15 p.m. ET on August 14, 2024 [1] - A conference call will follow at 4:30 p.m. ET on the same day, including a question and answer session [1] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [3] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes from biological fluids [3] - The device is designated as a Breakthrough Device by the FDA for treating advanced or metastatic cancer and life-threatening viruses [3]

Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to as ...

Financial Performance - For the fiscal year ended March 31, 2024, the company reported a net loss of $12,208,174, an increase from the net loss of $12,029,786 for the fiscal year ended March 31, 2023[292]. - Consolidated operating expenses for the fiscal year ended March 31, 2024 were $12,636,568, compared to $12,472,883 for the fiscal year ended March 31, 2023, reflecting an increase of $163,685[288]. - The company reported a significant increase in payroll and related expenses, primarily due to separation expenses for a former executive, totaling $861,994[289]. - In the fiscal year ended March 31, 2024, the company raised approximately $1,322,383 from the issuance of common stock, a significant decrease from $8,927,211 raised in the previous fiscal year[314]. - Net cash used in operating activities was approximately $10,130,000 in fiscal 2024, a slight decrease from $10,505,000 in fiscal 2023, primarily due to a positive change in working capital[311]. - The company expects to continue incurring increasing negative cash flows and net losses for the foreseeable future, necessitating further capital raises[305]. Cash and Working Capital - The company had a cash balance of $5,441,978 and working capital of $4,395,889 as of March 31, 2024, down from a cash balance of $14,532,943 and working capital of $13,585,478 at March 31, 2023[293]. - The company currently has over $9.1 million in cash and cash equivalents, but there is substantial doubt that this will sustain operations for 12 months beyond the filing date of the financial statements[307]. - The gross proceeds from a recent public offering were approximately $4.7 million, intended for general corporate purposes including clinical trial expenses and working capital[325]. - The company raised aggregate net proceeds of $8,927,211 in fiscal 2023, which was significantly higher than the $1,322,383 raised in fiscal 2024[303]. Clinical Trials and Product Development - The Hemopurifier has been designated as a "Breakthrough Device" by the FDA for oncology and life-threatening viral infections, with ongoing clinical trials planned in Australia and India[267][268]. - The company is investigating the Hemopurifier's potential applications in organ transplantation, focusing on removing harmful substances from recovered organs[281]. - The company has received ethics review board approval for clinical trials in India to treat severe COVID-19, with two sites currently involved[278][279]. - The company is working with North American Science Associates, LLC to manage planned clinical trials for the Hemopurifier in oncology indications in the U.S. and Australia[269]. - The company expects clinical trial expenses to increase for the foreseeable future, including costs related to manufacturing additional Hemopurifiers[304]. Market and Economic Conditions - The company plans to access equity markets for additional capital, but there is no assurance that this will be successful due to potential worsening global economic conditions[308]. - The average price per share for common stock sold under the 2022 ATM Agreement was $4.47 in fiscal 2024, compared to $11.93 in fiscal 2023[302][303]. - The company has $5,302,617 of 2022 ATM Shares remaining available for sale under the 2022 ATM Agreement as of March 31, 2024[298].

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medic ...

Core Viewpoint - Aethlon Medical, Inc. is advancing its Hemopurifier technology aimed at treating cancer and life-threatening infectious diseases, with recent clinical trial approvals and financial updates indicating progress in its operations and research initiatives [1][5]. Company Updates - Aethlon Medical is focused on the clinical development of its Hemopurifier, which is designed to remove harmful exosomes and viruses from blood, with applications in oncology and organ transplantation [2]. - The company received full ethics approval for a clinical trial of the Hemopurifier in cancer patients, valid until June 13, 2027, to be conducted in Australia [3]. - The Hemopurifier aims to improve response rates to anti-PD-1 therapies, as only about 30% of patients respond to treatments like pembrolizumab or nivolumab [4]. Financial Results - As of March 31, 2024, Aethlon Medical reported a cash balance of approximately $5.4 million, which increased to about $9.1 million by June 25, 2024 [8]. - Consolidated operating expenses for the fiscal year ended March 31, 2024, were approximately $12.6 million, a slight increase from $12.5 million in the previous year, primarily due to payroll increases [8][9]. - The net loss for the fiscal year ended March 31, 2024, was $12.2 million, compared to $12.0 million for the previous fiscal year [11]. Clinical Trials and Research - The company is progressing towards oncology trials in Australia and India, with expectations to enroll the first patient by the end of 2024 [5]. - Aethlon is also conducting a COVID-19 trial in India, with one patient treated so far, while monitoring a new COVID-19 subvariant [6]. - The Hemopurifier has shown potential in capturing previous strains of the H5N1 virus, although it has not been tested against the current strain [7].

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.Management will host a conference call on Thursday, June 27, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal ...

Industry Overview - The solid tumor therapeutics market is projected to grow from USD 222.71 billion in 2023 to USD 885.44 billion over the next decade, driven by increased pharmaceutical investments in R&D [1] - North America holds the largest share of the global solid tumor therapeutics market, accounting for 44% [1] Company Developments - Aethlon Medical, Inc. received full ethics approval for a clinical trial of its Hemopurifier® in cancer patients with solid tumors, valid until June 13, 2027 [2] - The trial aims to assess the safety, feasibility, and dose-finding of the Hemopurifier® in patients undergoing anti-PD-1 monotherapy, such as Keytruda® or Opdivo® [2][4] - Aethlon's Hemopurifier® is designed to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies [3][11] Clinical Trial Insights - The trial will involve approximately 18 patients and will monitor safety and adverse events, as well as changes in EV concentrations [4] - Patients not responding to initial therapy will enter the Hemopurifier® treatment phase, receiving up to three treatments within a week [4] Competitive Landscape - Current therapies like Keytruda® and Opdivo® have a lasting clinical response rate of only about 30% [3] - AbbVie has made significant moves in the solid tumor market, including the acquisition of ImmunoGen to enhance its portfolio [8] - AbbVie is advancing a differentiated pipeline in solid tumors, showcasing its innovative antibody-drug conjugate (ADC) platform at ASCO 2024 [9] Research and Development Trends - Major pharmaceutical companies are heavily investing in R&D, with Roche expected to lead with USD 14 billion by 2026, followed by Johnson & Johnson and Merck & Co. [11] - Aethlon Medical's focus on tumor-derived exosomes addresses a significant unmet need in cancer care, highlighting the evolving understanding of exosomes in cancer treatment [11]

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, ...